Urticaria | Treatment Algorithms: Claims Data Analysis | Chronic Spontaneous Urticaria | US | 2024

The drug market for chronic spontaneous urticaria (CSU; previously known as chronic idiopathic urticaria) is dominated by oral medications, including those approved (e.g., first- and second-generation antihistamines) or used off-label (e.g., DMARDs, immunosuppressants, tricyclic antidepressants) for this disorder. However, several drug classes have serious side effects, and many patients still struggle to control their symptoms. Novartis / Roche’s Xolair was the first FDA-approved biologic for CSU treatment, and other biologics are used off-label. Although guidelines for CSU treatment were updated to remove montelukast, prescribing of this agent continues to be robust.

Questions answered

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed CSU patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed CSU patients?
• How have Xolair and Dupixent been integrated into the treatment algorithm, and what are their sources of business?
• What percentage of CSU patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
• What percentage of CSU patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Markets covered: United States

Key companies: Roche / Novartis, Sanofi / Regeneron, AbbVie, Amgen, Samsung Bioepis, Merck, Sandoz

Key drugs: Xolair, Dupixent, montelukast, Vistaril, Zyrtec, Xyzal, Periactin, Claritin, Allegra, Benadryl, adalimumab, infliximab

Key analysis provided: Brand / therapy usage across longitudinal patient sample, newly diagnosed patient analysis, treatment initiation and progression, line of therapy analysis, combination therapy analysis, source of business for recently treated patients, persistency and compliance analysis, product-level patient flowcharts

Key feature: Dashboard featuring interactive visuals, easy navigation, and expanded analyses